Precision oncology has long been discussed as the future of cancer care, initially focused on advanced disease management and treatment selection. Today, Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) are expanding that vision beyond late-stage care and into earlier detection, longitudinal monitoring, and survivorship. These technologies are helping move precision medicine from concept to operational reality, creating new opportunities — and new strategic considerations — for health system leaders.
For health systems, MRD and MCED are more than emerging tools. They represent a broader shift in how organizations approach cancer care delivery across the continuum. MRD introduces molecular insights into pre and post-treatment monitoring and surveillance, while MCED has the potential to move cancer detection upstream through earlier screening and diagnosis. The hope is to increase demand for early intervention and coordinated care while reshaping how systems think about oncology services overall.
That is why many organizations are beginning to view MRD and MCED not simply as clinical innovations, but as enterprise-level strategy discussions. These technologies do not fit neatly within traditional silos. Their value depends heavily on what happens before and after testing, requiring alignment across screening, diagnosis, treatment, surveillance, and survivorship workflows.
For MCED specifically, implementation extends well beyond oncology. Screening and patient identification often begin in primary care and population health settings before a patient ever enters the cancer care pathway. MRD, meanwhile, requires consistent integration into treatment planning and surveillance strategies following diagnosis. As adoption grows, organizations will need to determine how these capabilities intersect with oncology service lines, laboratory medicine, radiology, navigation, informatics, digital health, and finance.
This makes governance a central consideration for executive leadership teams. Questions around patient selection, result routing, follow-up pathways, outcomes tracking, and care coordination are not departmental issues — they are enterprise-wide operational decisions. Organizations that establish clear ownership and cross-functional alignment will likely be better positioned to scale these technologies effectively.
The broader implications may also extend into service-line planning and resource allocation. Earlier-stage cancer detection could increase demand for surgical oncology, radiation oncology, multidisciplinary care coordination, and survivorship services. At the same time, MRD may create new expectations for ongoing surveillance and longitudinal patient management following treatment. While advanced-stage cancer management will remain critical, the balance of care delivery may evolve as more cancers are identified and treated earlier.
One modeling analysis projected that full adoption of MCED screening could reduce Stage IV cancer diagnoses in the U.S. population by 45%.¹ For health systems, that raises important questions around workforce planning, infrastructure readiness, and long-term operational strategy.
At the same time, fragmented adoption carries risk. Isolated pilots, disconnected workflows, or siloed digital and analytics efforts may limit both operational efficiency and clinical impact. The organizations likely to realize the greatest value will be those that focus on building coordinated pathways, standardized governance, and scalable operational models across the continuum.
The near-term goal for many systems is not enterprise-wide standardization overnight, but rather establishing a thoughtful framework for evaluation, implementation, and growth. Some organizations may begin with MRD programs in disease areas where workflows are already established, while others may explore tightly governed MCED initiatives with clearly defined diagnostic and follow-up pathways. In either case, success will depend on aligning stakeholders, defining accountability, monitoring downstream impact, and scaling responsibly.
Although MRD and MCED address different points in the cancer journey, they ultimately raise the same strategic question for health systems: how can organizations integrate molecular insights into a coordinated, enterprise-wide model for screening, treatment selection, surveillance, and survivorship? The answer may shape the next phase of precision oncology adoption across healthcare.
Reference:
1. Chhatwal J, Xiao J, et al. The impact of multicancer early detection tests on cancer stage shift: A 10-year microsimulation model. Cancer. 2025;131(22):e70075.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
